Physician profile
Michael A Drapcho
NPI 1316981475
$2,517.59
in general payments reported to CMS, 2019-2025
25 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $405 · 2021: $677 · 2022: $41.27 · 2023: $198 · 2024: $136 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $661.53 | 2021 | |
| Novo Nordisk INC | $345.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $198.24 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $177.46 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.52 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $128.18 | 2019-2024 | Shingrix, Arexvy |
| Abbvie INC. | $118.87 | 2021-2025 | Qulipta, Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $110.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $94.46 | 2019-2020 | |
| Lilly USA, LLC | $90.83 | 2019-2023 | Mounjaro |
| Abbott Laboratories | $85.69 | 2023-2024 | Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $82.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $47.85 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.82 | 2019 | |
| Allergan, INC. | $35.04 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.16 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $17.62 | 2019 | |
| Daiichi Sankyo INC. | $16.60 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.95 | 2019 | |
| Sumitomo Pharma America, INC. | $15.02 | 2023 | Gemtesa |
| Exact Sciences Corporation | $13.85 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $13.54 | 2023 | Watchman Flx |
| Sanofi Pasteur INC. | $12.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.92 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Drapcho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.